112 related articles for article (PubMed ID: 15659885)
1. Formal approval for Fuzeon.
AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
[No Abstract] [Full Text] [Related]
2. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
Moreno Alvarez PJ
Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
[No Abstract] [Full Text] [Related]
3. Misleading efficacy claims for Fuzeon.
AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16247841
[No Abstract] [Full Text] [Related]
4. Clinical trials for enfuvirtide (Fuzeon, T-20).
Crabb C
AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
[No Abstract] [Full Text] [Related]
5. Fuzeon combination highly effective.
AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
[No Abstract] [Full Text] [Related]
6. T-1249 development suspended.
Huff B
GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
[No Abstract] [Full Text] [Related]
7. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
Pham PA
Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
[No Abstract] [Full Text] [Related]
8. Enfuvirtide, a new drug for HIV infection.
Fletcher CV
Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873
[No Abstract] [Full Text] [Related]
9. US FDA approves new class of HIV therapeutics.
Robertson D
Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
[No Abstract] [Full Text] [Related]
10. Enfuvirtide approved for defusing HIV.
Burton A
Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
[No Abstract] [Full Text] [Related]
11. [New drug class blocks virus-cell fusion. HIV not admitted].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
[No Abstract] [Full Text] [Related]
12. Enfuvirtide doubles chances for suppression.
AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
[No Abstract] [Full Text] [Related]
13. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
[No Abstract] [Full Text] [Related]
14. [Enfuvirtide. Two injections per day for HIV].
Taéron C
Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
[No Abstract] [Full Text] [Related]
15. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
16. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
[No Abstract] [Full Text] [Related]
17. T-20 being called "miraculous".
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
[No Abstract] [Full Text] [Related]
18. Fuzeon treatment forum, January 2004.
Burgess GE
Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
[No Abstract] [Full Text] [Related]
19. [Editorial: Interview with Father Hervé Gallais, Conception Hospital, Marseille].
Med Mal Infect; 2004 Sep; 34 Spec No 1():1-2. PubMed ID: 15742548
[No Abstract] [Full Text] [Related]
20. Katy, bar the door! HIV entry inhibitors.
Martinez LJ
Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
